Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,025.26 -10.43 (-0.21%) Dow
37,957.82 +141.90 (+0.38%) Nasdaq
15,620.38 -37.44 (-0.24%) Bitcoin USD
57,222.37 -2,846.92 (-4.74%) CMC Crypto 200
1,191.78 -147.28 (-11.00%)
Amarin Corporation plc (AMRN)
- GuruFocus.com
Amarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic Focus
Revenue Declines Amidst Generic Competition, Yet Strategic Initiatives Show Promise
- GlobeNewswire
Amarin Reports First Quarter 2024 Business Update and Financial Results
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK-- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Following UK High Court Approval in Second Quarter 2024 -- -- Company to Host
- GlobeNewswire
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect PatientsDUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug Administration (FDA) requesting that the Commissioner focus on and take further action to address significant off-label prescribing of fe
